DOCSLIB.ORG

Immunomodulation by Adipokines in Type 1 Diabetes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immunomodulation by Adipokines in Type 1 Diabetes IMMUNOMODULATION BY ADIPOKINES IN TYPE 1 DIABETES By Myriam Chimen A thesis submitted to The University of Birmingham For the degree of DOCTOR OF PHILOSOPHY School of Clinical and Experimental Medicine College of Medical and Dental Sciences University of Birmingham Date: February 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Abstract Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease in which the immune system specifically targets and destroys the pancreatic insulin-producing beta-cells. We are interested in defining whether adipose tissue-derived cytokines (adipokines) such as adiponectin (anti-inflammatory) and leptin (pro-inflammatory) could influence T1D progression. We first demonstrate the expression of the leptin receptor (LEPR) on peripheral blood mononuclear cells (PBMC) and observed higher expression of LEPR on PBMC from patients with T1D. However, we found no significant functional relevance for this observation. On the other hand, we show lower expression of the adiponectin receptors on lymphocytes from patients with T1D. This was associated with a reduced capacity of adiponectin to inhibit lymphocyte trans-endothelial migration in T1D. Remarkably, we show that adiponectin strongly inhibited lymphocyte migration either by action on the endothelium or directly on the lymphocytes. We have now established that this effect on lymphocytes is mediated by a newly identified B cell-secreted agent following adiponectin stimulation. The agent stimulates endothelial production of sphingosine-1-phosphate, which in turn is responsible for the inhibition of lymphocyte trans-endothelial migration. These observations were confirmed in vivo using a peritoneal model of inflammation in a B cell knock-out mouse strain. In these animals, T cell recruitment in the peritoneum is increased compared to the wild-type and restored when the agent was administrated. These observations underline the importance of adiponectin in the control of lymphocyte transmigration during an inflammatory response and offer a potential therapeutic agent for T1D as well as other T cell-mediated diseases. Acknowledgements I would firstly like to thank my supervisor Dr Parth Narendran for giving me the opportunity to work on that intringuing project, for your precious advices, guidance and corrections and your patience and kindness. I also would like to thank my “adopted” supervisor Dr Ed Rainger for your help with the transmigration project. Thank you for your “strokes of genius”, your supervision, your enthusiasm with the project and your help with my thesis. I would also like to thank my second supervisor, Dr Peter Lane, for your advices. Then I would like to thank Helen, for introducing me to the world of lymphocyte migration, for contributing to the project and for the help with my thesis. I would like to thank Dr Ashley Martin for your help with the proteomics and for being so clear and patient at explaining the world of mass spectrometry to me. I also thank Dr Francesca Barone, Gemma and Prof Chris Buckley for helping me out with the mice experiments. I would like to thank the other people in the Narendran lab, Terence, Suzy, Ed, Amy and Manita. I would also like to thank everyone in the Samson and Walker labs for their precious advices on proper immunology science and for the exchange of reagents. I would also like to thank all the people in the Link lab, especially Clara and Phil. I also want to thank all the donors who kindly donated their blood. I also thank the people from the Hagedorn Institute and Novo Nordisk who were so welcoming and nice to me over my stay and for the reagents. Then I would like to thank all my desk neighbours, now friends, Ange, Pushpa, Donna, Ana for their support, coffee breaks and always finding the words to make me laugh. Also thanks for coping with my computer moaning. I would also like to thank my family for their great support, love, advices and for always encouraging and pushing me to do what I want in life. Finally but not the last, I would like to thank Phil, my partner, best friend and love for always giving me great support, always pushing me forward and especially putting up with me. Thank you for being there and for your love, I feel very lucky to have you in my life. Table of contents Chapter 1- GENERAL INTRODUCTION .................................................... 1 1. Type 1 diabetes (T1D) disease ........................................................................................... 2 1.1. Clinical aspects of T1D .............................................................................................. 2 1.2. Prevalence of T1D ...................................................................................................... 4 1.3. Immunity and pathogenesis of T1D ........................................................................... 6 1.3.1. Autoimmunity in T1D .......................................................................................... 6 1.3.2. Trafficking and recruitment of lymphocytes during inflammation .................... 13 1.3.3. Vascular function in T1D ................................................................................... 24 2. T1D, obesity and insulin resistance .................................................................................. 26 3. Adipokines ........................................................................................................................ 28 3.1. Leptin ........................................................................................................................ 28 3.1.1. Pleiotropic properties of leptin ........................................................................... 28 3.1.2. Leptin in immunity ............................................................................................. 30 3.1.3. Leptin in T1D ..................................................................................................... 34 3.2. Adiponectin .............................................................................................................. 37 3.2.1. Adiponectin and its receptors ............................................................................. 37 3.2.2. Adiponectin role in metabolism ......................................................................... 39 3.2.3. Anti-inflammatory properties of adiponectin ..................................................... 40 3.2.4. Adiponectin modulates immune cell migration ................................................. 43 3.2.5. Adiponectin in T1D ............................................................................................ 45 4. Hypothesis and aims ........................................................................................................ 46 CHAPTER 2-MATERIAL AND METHODS ........................................... 47 1. Material ............................................................................................................................. 48 1.1. List of main reagents ................................................................................................ 48 1.2. Antibodies ................................................................................................................. 49 2. Methods ............................................................................................................................ 50 2.1. Measurement of gene expression ............................................................................. 50 2.1.1. PBMC isolation .................................................................................................. 50 2.1.2. RNA extraction ................................................................................................... 50 2.1.3. Reverse transcription .......................................................................................... 53 2.1.4. Conventional PCR .............................................................................................. 53 2.1.5. Real-Time PCR .................................................................................................. 54 2.2. Measurement of protein expression .......................................................................... 55 2.2.1. Flow cytometry ................................................................................................... 55 2.2.2. Western Blot ....................................................................................................... 56 2.3. ELISA assay ............................................................................................................. 56 Table of contents 2.4. Cell sorting ............................................................................................................... 57 2.4.1. Positive selection of PBMC subsets ................................................................... 57 2.4.2. Negative selection of PBMC subsets ................................................................. 57 2.5. DCs Phenotyping
Load more

Recommended publications
  • An Endocytosis Pathway Initiated Through Neuropilin-1 and Regulated by Nutrient Availability
    ARTICLE Received 18 Apr 2014 | Accepted 2 Aug 2014 | Published 3 Oct 2014 DOI: 10.1038/ncomms5904 An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability Hong-Bo Pang1, Gary B. Braun1,2, Tomas Friman1,2, Pedro Aza-Blanc1, Manuel E. Ruidiaz1, Kazuki N. Sugahara1,3, Tambet Teesalu1,4 & Erkki Ruoslahti1,2 Neuropilins (NRPs) are trans-membrane receptors involved in axon guidance and vascular development. Many growth factors and other signalling molecules bind to NRPs through a carboxy (C)-terminal, basic sequence motif (C-end Rule or CendR motif). Peptides with this motif (CendR peptides) are taken up into cells by endocytosis. Tumour-homing CendR peptides penetrate through tumour tissue and have shown utility in enhancing drug delivery into tumours. Here we show, using RNAi screening and subsequent validation studies, that NRP1-mediated endocytosis of CendR peptides is distinct from known endocytic pathways. Ultrastructurally, CendR endocytosis resembles macropinocytosis, but is mechanistically different. We also show that nutrient-sensing networks such as mTOR signalling regulate CendR endocytosis and subsequent intercellular transport of CendR cargo, both of which are stimulated by nutrient depletion. As CendR is a bulk transport pathway, our results suggest a role for it in nutrient transport; CendR-enhanced drug delivery then makes use of this natural pathway. 1 Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, USA. 2 Center for Nanomedicine, Department of Cell, Molecular and Developmental Biology, University of California Santa Barbara, Santa Barbara, California 93106-9610, USA. 3 Department of Surgery, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA.
    [Show full text]
  • Exploring the Extracellular Regulation of the Tumor Angiogenic Interaction
    bioRxiv preprint doi: https://doi.org/10.1101/581884; this version posted March 18, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Exploring the extracellular regulation of the tumor angiogenic in- teraction network using a systems biology model Ding Li1 and Stacey D. Finley2 1Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA 2Department of Biomedical Engineering; Mork Family Department of Chemical Engineering and Materials Sci- ence; Department of Biological Sciences, University of Southern California, Los Angeles, CA, USA ABSTRACT angiogenic signaling to oppose angiogenesis4,5. Considering Tumor angiogenesis is regulated by pro- and anti-angiogenic factors. the importance of angiogenesis in tumor development, anti- Anti-angiogenic agents target the interconnected network of angio- angiogenic therapies are designed to target the signaling of genic factors to inhibit neovascularization, which subsequently im- angiogenic factors to inhibit neovascularization and tumor pedes tumor growth. Due to the complexity of this network, optimizing growth6. Single-agent anti-angiogenic therapies that target a anti-angiogenic cancer treatments requires detailed knowledge at a particular angiogenic factor in the network were the first angi- systems level. In this study, we constructed a tumor tissue-based ogenesis-inhibiting therapies studied. These include antibod- model to better understand how the angiogenic network is regulated ies or small molecules targeting pro-angiogenic factors7 and by opposing mediators at the extracellular level. We consider the net- peptide mimetics of anti-angiogenic factors8.
    [Show full text]
  • Investigation of the Underlying Hub Genes and Molexular Pathogensis in Gastric Cancer by Integrated Bioinformatic Analyses
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Investigation of the underlying hub genes and molexular pathogensis in gastric cancer by integrated bioinformatic analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The high mortality rate of gastric cancer (GC) is in part due to the absence of initial disclosure of its biomarkers. The recognition of important genes associated in GC is therefore recommended to advance clinical prognosis, diagnosis and and treatment outcomes. The current investigation used the microarray dataset GSE113255 RNA seq data from the Gene Expression Omnibus database to diagnose differentially expressed genes (DEGs). Pathway and gene ontology enrichment analyses were performed, and a proteinprotein interaction network, modules, target genes - miRNA regulatory network and target genes - TF regulatory network were constructed and analyzed. Finally, validation of hub genes was performed. The 1008 DEGs identified consisted of 505 up regulated genes and 503 down regulated genes.
    [Show full text]
  • Neuropilin-1
    November 3, 2020 Edition 2020-11-03 *** Available on-line at https://www.cdc.gov/library/covid19 *** Neuropilin-1 The SARS-CoV-2 major spike protein (S) is cleaved by a host protease to create S1 and S2 functional polypeptides. The S1 polypeptide has a carboxy-terminal sequence that binds to host cell surface neuropilin-1 (NRP1) and neuropilin-2 (NRP2) receptors. NRP receptors facilitate viral entry for several viruses due to their abundance on cells that are exposed to the external environment – cells that paradoxically express low levels of angiotensin- converting enzyme-2 (ACE2), the known SARS-CoV-2 receptor. Here we present two articles that evaluated the potential for NRP1 to act as a co-receptor for SARS-CoV-2. PEER-REVIEWED Neuropilin-1 is a host factor for SARS-CoV-2 infection. Daly et al. Science (October 20, 2020). Key findings: • The S1 fragment of the cleaved SARS-CoV-2 spike protein binds to the cell surface receptor neuropilin-1 (NRP1). • SARS-CoV-2 utilizes NRP1 for cell entry as evidenced by decreased infectivity of cells in the presence of: o NRP1 deletion (p <0.0001) (Figure). o Three different anti-NRP1 monoclonal antibodies (p <0.001). o Selective NRP1 antagonist, EG00229 (p <0.01). Methods: Binding of the S1 fragment to NRP1 was assessed and ability of SARS-CoV-2 to use NRP1 to infect cells was measured in angiotensin-converting enzyme-2 (ACE-2)-expressing cell lines by knocking out NRP1 expression, blocking NRP1 with 3 different anti-NRP1 monoclonal antibodies, or using NRP1 small molecule antagonists.
    [Show full text]
  • Microrna-320A Inhibits Tumor Invasion by Targeting Neuropilin 1 and Is Associated with Liver Metastasis in Colorectal Cancer
    ONCOLOGY REPORTS 27: 685-694, 2012 microRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer YUJUN ZHANG1, XIANGJUN HE1, YULAN LIU1,2, YINGJIANG YE3, HUI ZHANG3, PEIYING HE1, QI ZHANG1, LINGYI DONG3, YUJING LIU1 and JIANQIANG DONG1 1Institute of Clinical Molecular Biology, and Departments of 2Gastroenterology and 3General Surgery, Peking University, People's Hospital, Beijing 100044, P.R. China Received September 13, 2011; Accepted October 26, 2011 DOI: 10.3892/or.2011.1561 Abstract. MicroRNAs (miRNAs) have been implicated Introduction in regulating diverse cellular pathways. Although there is emerging evidence that various miRNAs function as onco- Colorectal cancer (CRC) is the second most common cause genes or tumor suppressors in colorectal cancer (CRC), the role of cancer-related death worldwide (1). Approximately 50% of of miRNAs in mediating liver metastasis remains unexplored. patients diagnosed with CRC die as a result of complications The expression profile of miRNAs in liver metastasis and from distant metastases, which occur mainly in the liver. The primary CRC tissues was analyzed by miRNA microarrays occurrence of liver metastasis ranges from 20% in stage II to and verified by real-time polymerase chain reaction (PCR). 70% in stage IV CRC patients, according to the UICC stage In 62 CRC patients, the expression levels of miR-320a were guidelines. Of all patients who die of advanced colorectal determined by real-time PCR, and the effects on migration and cancer (ACRC), 60-70% display liver metastasis (2). Metastasis invasion of miR-320a were determined using a transwell assay. to the liver is the major cause of death in CRC patients (3).
    [Show full text]
  • A Dominant Negative Receptor for Specific
    The Journal of Neuroscience, September 15, 1999, 19(18):7870–7880 A Dominant Negative Receptor for Specific Secreted Semaphorins Is Generated by Deleting an Extracellular Domain from Neuropilin-1 Michael J. Renzi, Leonard Feiner, Adam M. Koppel, and Jonathan A. Raper Department of Neurosciences, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6074 Neuropilins have recently been characterized as receptors for plasmic domain fails to act as a dominant negative receptor secreted semaphorins. Here, we report the generation of a component. These results suggest that neuropilin-1 is a nec- dominant negative form of neuropilin-1 by the deletion of one of essary component of receptor complexes for some, but not all, its extracellular domains. Expression of this variant in cultured secreted semaphorin family members. Overexpression of dom- primary sympathetic neurons blocks the paralysis of growth inant negative neuropilins should provide a powerful new cone motility normally induced by SEMA-3A (collapsin-1, method of blocking the functions of secreted semaphorins. semaphorin III, semaphorin D) and SEMA-3C (collapsin-3, Key words: semaphorin; collapsin; neuropilin-1; sympathetic semaphorin E) but not that induced by SEMA-3F (semaphorin neuron; growth cone guidance; growth cone collapse; domi- IV). A truncated form of neuropilin-1 that is missing its cyto- nant negative receptor The development of a functional nervous system requires that Giger et al., 1998a,b) and are likely to act as repellents that help axons navigate through a complex environment, sometimes over guide peripheral axons, particularly sympathetic axons, along long distances, to locate their correct targets. At the growing tips their appropriate trajectories.
    [Show full text]
  • High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity Stephanie K
    Published OnlineFirst August 17, 2016; DOI: 10.1158/1541-7786.MCR-16-0153 Metabolism Molecular Cancer Research High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity Stephanie K. Doerner1, Edimara S. Reis2, Elaine S. Leung3, Justine S. Ko1, Jason D. Heaney4,5, Nathan A. Berger1,6, John D. Lambris2, and Joseph H. Nadeau1,3 Abstract Obesity and related metabolic disturbances are closely asso- and generation of C5a, which in turn induces the production of ciated with pathologies that represent a significant burden to proinflammatory cytokines and expression of proto-oncogenes. global health. Epidemiological and molecular evidence links Pharmacological and genetic targeting of the C5a receptor obesity and metabolic status with inflammation and increased reduced both inflammation and intestinal polyposis, suggest- risk of cancer. Here, using a mouse model of intestinal neo- ing the use of complement inhibitors for preventing diet- plasia and strains that are susceptible or resistant to diet- induced neoplasia. induced obesity, it is demonstrated that high-fat diet-induced inflammation, rather than obesity or metabolic status, is asso- Implications: This study characterizes the relations between diet ciated with increased intestinal neoplasia. The complement and metabolic conditions on risk for a common cancer and fragmentC5aactsasthetriggerforinflammation and intestinal identifies complement activation as a novel target for cancer tumorigenesis. High-fat diet induces complement activation prevention. Mol Cancer Res; 14(10); 953–65. Ó2016 AACR. Introduction Supporting a role for diet-induced obesity (DIO) in promoting inflammation and cancer, levels of IL6 and tumor burden are both Obesity is an increasingly important risk factor for many ob ob reduced following azoxymethane treatment of obese Lep / mice cancers (1, 2).
    [Show full text]
  • Leptin As a Uremic Toxin Interferes with Neutrophil Chemotaxis
    J Am Soc Nephrol 15: 2366–2372, 2004 Leptin as a Uremic Toxin Interferes with Neutrophil Chemotaxis LUCIANO OTTONELLO,* PAOLA GNERRE,* MARIA BERTOLOTTO,* MARINA MANCINI,* PATRIZIA DAPINO,* RODOLFO RUSSO,† GIACOMO GARIBOTTO,† TOMMASO BARRECA,* and FRANCO DALLEGRI* *Division of Internal Medicine and †Division of Nephrology, Department of Internal Medicine and Medical Specialties, University of Genoa Medical School, Genoa, Italy Abstract. Leptin is a pleiotropic molecule involved in energy Finally, the serum inhibitory activity can be effectively prevented homeostasis, hematopoiesis, inflammation, and immunity. Hypo- by immune depletion of leptin. The results also show, however, leptinemia characterizing starvation has been strictly related to that leptin by itself is endowed with chemotactic activity toward increased susceptibility to infection secondary to malnutrition. neutrophils. The two activities—inhibition of the cell response to Nevertheless, ESRD is characterized by high susceptibility to chemokines and stimulation of neutrophil migration—could be bacterial infection despite hyperleptinemia. Defects in neutrophils detected at similar concentrations. On the contrary, neutrophils 2ϩ play a crucial role in the infectious morbidity, and several uremic exposed to leptin did not display detectable [Ca ]i mobilization, ␤ toxins that are capable of depressing neutrophil functions have oxidant production, or 2-integrin upregulation. The results dem- been identified. Only a few and contrasting reports about leptin onstrate that leptin is
    [Show full text]
  • Signals of the Neuropilin-1–MET Axis and Cues of Mechanical Force Exertion Converge to Elicit Inflammatory Activation in Coherent Endothelial Cells
    Signals of the Neuropilin-1−MET Axis and Cues of Mechanical Force Exertion Converge to Elicit Inflammatory Activation in Coherent Endothelial Cells This information is current as of September 27, 2021. Maryam Rezaei, Ana C. Martins Cavaco, Jochen Seebach, Stephan Niland, Jana Zimmermann, Eva-Maria Hanschmann, Rupert Hallmann, Hermann Schillers and Johannes A. Eble J Immunol published online 28 January 2019 Downloaded from http://www.jimmunol.org/content/early/2019/01/27/jimmun ol.1801346 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2019/01/27/jimmunol.180134 Material 6.DCSupplemental Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2019 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published January 28, 2019, doi:10.4049/jimmunol.1801346 The Journal of Immunology Signals of the Neuropilin-1–MET Axis and Cues of Mechanical Force Exertion Converge to Elicit Inflammatory Activation in Coherent Endothelial Cells Maryam Rezaei,* Ana C.
    [Show full text]
  • CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
    CDER Breakthrough Therapy Designation Approvals Data as of December 31, 2020 Total of 190 Approvals Submission Application Type and Proprietary Approval Use Number Number Name Established Name Applicant Date Treatment of patients with previously BLA 125486 ORIGINAL-1 GAZYVA OBINUTUZUMAB GENENTECH INC 01-Nov-2013 untreated chronic lymphocytic leukemia in combination with chlorambucil Treatment of patients with mantle cell NDA 205552 ORIGINAL-1 IMBRUVICA IBRUTINIB PHARMACYCLICS LLC 13-Nov-2013 lymphoma (MCL) Treatment of chronic hepatitis C NDA 204671 ORIGINAL-1 SOVALDI SOFOSBUVIR GILEAD SCIENCES INC 06-Dec-2013 infection Treatment of cystic fibrosis patients age VERTEX PHARMACEUTICALS NDA 203188 SUPPLEMENT-4 KALYDECO IVACAFTOR 21-Feb-2014 6 years and older who have mutations INC in the CFTR gene Treatment of previously untreated NOVARTIS patients with chronic lymphocytic BLA 125326 SUPPLEMENT-60 ARZERRA OFATUMUMAB PHARMACEUTICALS 17-Apr-2014 leukemia (CLL) for whom fludarabine- CORPORATION based therapy is considered inappropriate Treatment of patients with anaplastic NOVARTIS lymphoma kinase (ALK)-positive NDA 205755 ORIGINAL-1 ZYKADIA CERITINIB 29-Apr-2014 PHARMACEUTICALS CORP metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients NDA 206545 ORIGINAL-1 ZYDELIG IDELALISIB GILEAD SCIENCES INC 23-Jul-2014 for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
    [Show full text]
  • Monocytes Improves Antiangiogenic Therapy in Colorectal Cancer
    Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer Keehoon Junga,1, Takahiro Heishia,1, Joao Incioa, Yuhui Huanga, Elizabeth Y. Beecha, Matthias Pintera, William W. Hoa,b, Kosuke Kawaguchia, Nuh N. Rahbaria, Euiheon Chunga,2, Jun Ki Kimc,3, Jeffrey W. Clarkd, Christopher G. Willette, Seok Hyun Yunc,f, Andrew D. Lusterg, Timothy P. Paderaa, Rakesh K. Jaina,4,5, and Dai Fukumuraa,4,5 aEdwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114; bDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; cWellman Center for Photomedicine, Department of Dermatology, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114; dDepartment of Hematology/Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114; eDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710; fDivision of Health Sciences and Technology, Harvard–Massachusetts Institute of Technology, Cambridge, MA 02139; and gCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114 Contributed by Rakesh K. Jain, August 10, 2017 (sent for review June 19, 2017; reviewed by Timothy T. Hla and Judith A. Varner) Antiangiogenic therapy with antibodies against VEGF (bevacizumab) (CXCL12)—also known as stromal cell-derived factor-1 alpha or VEGFR2 (ramucirumab) has been proven efficacious in colorectal (SDF-1α)—in primary tumor biopsies from rectal cancer patients cancer (CRC) patients. However, the improvement in overall survival treated with the anti-VEGF antibody bevacizumab compared with is modest and only in combination with chemotherapy.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]